Convergent Therapeutics News and Activities

View the org chart displaying its 22 main executives

Most searched biographies at Convergent Therapeutics

• Philip Kantoff, Co-Founder and Chief Executive Officer
• Neil Bander, Director
• Michael Rossi, Director

Popular executive movements at Convergent Therapeutics

• Andrew Davis has joined the company as Chief Business and Strategy Officer  (posted on April 29 2026).
• Michael Rossi has joined the company as Director  (posted on March 19 2026).
• Caitlyn Harvey, who was Vice President, Head of Chemistry, Manufacturing and Controls, is promoted to Senior Vice President, Technical Operations  (posted on March 19 2026).

Click here to view some more movements at Convergent Therapeutics

Create your alert
to follow the executive moves at Convergent Therapeutics.

Convergent Therapeutics has 2,426 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• The new name of ChemoTech is Neem’s Hill. (posted on July 14 2026).
• MindRank has just announced a $52 Million fundraising (posted on July 14 2026).
• Chemomab and Scipher Medicine have announced they will merge  (posted on July 13 2026)..

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by Convergent Therapeutics

• Convergent raises $90M to develop its radiopharmaceutical for prostate cancer
• Convergent Therapeutics Appoints Barbara Duncan to Board of Directors
• Convergent Therapeutics Announces First Shipments of Actinium 225 from Cardinal Health to Support the CONVERGE-01 Phase 2 Clinical Trial
• Convergent Therapeutics Announces First Patient Treated in Phase II Clinical Trial with Lead Therapeutic Candidate and Corporate Updates
• Convergent Therapeutics Announces FDA Clearance of IND Application for CONV01-α, a Best-in-Class Radioantibody Targeting Prostate-Specific Membrane Antigen
• NorthStar Medical Radioisotopes and Convergent Therapeutics Announce Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)
• Convergent Therapeutics Appoints Scott Myers as Chairman of its Board of Directors
• View more press releases Close

Social media about Convergent Therapeutics

• Convergent Therapeutics on Wikipedia, Google News & Yahoo Finance
• Convergent Therapeutics on LinkedIn, X (Twitter) & YouTube